EUCTR2012-002281-12-IT进行中（未招募）不适用
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART. - not applicable
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Completed immunization regimen with Vacc-4x active and stopped ART (at Week 28) in the CT-BI Vacc-4x 2007/1 study(No re-start of ART is required). 2. Documented pre-study CD4 cell count =400x10e6/L. 3. Documented pre-study viral load < 300.000 copies/mL. 4. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Reported AIDS-defining illness within the previous year. 2. Malignant disease. 3. On chronic treatment with immune-suppressive therapy. 4. Unacceptable values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine values >1.5x upper limit of normal (ULN), and AST, ALT and alkaline phosphatase (ALP)values >2.5x ULN. 5. Concurrent chronic active infection such as viral hepatitis B or C or tuberculosis. 6. Pregnant or breastfeeding women. 7. Women of childbearing potential not using reliable and adequate contraceptive methods (defined as: use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; practicing abstinence; sterile) during the 5 weeks re-boosting period including the DTH and for 2 weeks after the DTH test, or sexually active male subjects with partners of child bearing potential, unwilling to practice effective contraception during the 5 weeks re-boosting period including the DTH and for 12 weeks after the DTH-test. 8. Current participation in other clinical therapeutic studies. 9. Incapability of compliance to treatment protocol, in the opinion of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical studySubjects Infected with HIV-1 Who Have Maintained an Adequate Response to ARTMedDRA version: 14.1 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 10021881 - Infections and infestationsEUCTR2012-002281-12-GBBionor Immuno AS40
进行中（未招募）
不适用
Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical studyEUCTR2012-002281-12-ESBionor Immuno AS40
进行中（未招募）
不适用
Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical studySubjects Infected with HIV-1 Who Have Maintained an Adequate Response to ARTMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-002281-12-DEBionor Immuno AS40
已完成
不适用
Additional acquisition of healthy subjects in the previous study "Longitudinal Observational Study of Atypical Pain in the Oral-Facial Region by Brain Imaging Analysis" (July 1, 2017 - July 31, 2021).healthy subjectsJPRN-UMIN000047476SHIZUOKA CITY SHIMIZU HOSPITA40
进行中（未招募）
1 期
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols - N/AEUCTR2010-020151-31-DEArQule, Inc.60